2025
76P: Long-term survival outcomes with first-line (1L) osimertinib monotherapy and subsequent treatment (tx) patterns: Final analysis of a real-world (rw) study in US patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC)
Griesinger F, Wang X, Karia P, Cooper M, Servidio L, Jedy-Agba E, Nieva J, Doroshow D. 76P: Long-term survival outcomes with first-line (1L) osimertinib monotherapy and subsequent treatment (tx) patterns: Final analysis of a real-world (rw) study in US patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC). Journal Of Thoracic Oncology 2025, 20: s56-s57. DOI: 10.1016/s1556-0864(25)00271-0.Peer-Reviewed Original Research
2024
HMA/Ven Treatment Modifications and Associated Outcomes in IDH -Mutant AML
Chin K, Derkach A, Famulare C, Gupta G, Borge P, Geyer M, Goldberg A, Haque T, Park J, Roeker L, Tallman M, Stahl M, Stein E. HMA/Ven Treatment Modifications and Associated Outcomes in IDH -Mutant AML. Blood 2024, 144: 5962-5962. DOI: 10.1182/blood-2024-211733.Peer-Reviewed Original ResearchAcute myeloid leukemiaMedian overall survivalIsocitrate dehydrogenase-mutantCommon Terminology Criteria for Adverse EventsMeasurable residual diseaseOverall survivalTreatment modificationNo significant differenceCR/CRi rateMRD negativityHypomethylating agentsSignificant differenceLong-term survival outcomesSingle-center retrospective studyToxicity associated with treatmentMutant acute myeloid leukemiaCycle lengthChemotherapy-ineligible patientsGrade 3 neutropeniaMRD-negativity ratesTreatment cycle characteristicsAssociated with higher responseEvent-free survivalKaplan-Meier methodologyEfficacious treatment regimensSequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Ascierto P, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, Cossu A, Mandalà M, Ferrucci P, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro M, Lebbe C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Cao M, Minisini A, De Placido S, Sanmamed M, Mallardo D, Paone M, Vitale M, Melero I, Grimaldi A, Giannarelli D, Dummer R, Sileni V, Palmieri G. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nature Communications 2024, 15: 146. PMID: 38167503, PMCID: PMC10761671, DOI: 10.1038/s41467-023-44475-6.Peer-Reviewed Original ResearchConceptsOverall survivalSurvival outcomesNoncomparative phase II trialTotal progression-free survivalLong-term survival outcomesMEK inhibitionBRAF/MEK inhibitionFirst-line treatment approachFirst-line treatment optionBRAF/MEK inhibitorsT-lymphocyte antigen-4Cell death protein 1BRAFV600-mutant melanomaDual checkpoint blockadeFirst-line immunotherapyMetastatic BRAF V600Serum interferon gammaPhase II trialProgression-free survivalDeath protein 1BRAFV600-mutant metastatic melanomaLow baseline levelsBiomarker analysisCombination BRAFSequential immunotherapyChapter 30 The emerging genetic landscape of renal cell carcinoma
Lee G, Shinder B, Sadimin E, Stephenson R, Singer E. Chapter 30 The emerging genetic landscape of renal cell carcinoma. 2024, 447-460. DOI: 10.1016/b978-0-12-822824-1.00035-3.ChaptersRenal cell carcinomaCell carcinomaOrgan-confined renal cell carcinomaKidney cancerMetastatic renal cell carcinomaLong-term survival outcomesLandscape of renal cell carcinomaDiagnosis of kidney cancerRenal tubule epithelial cellsTubule epithelial cellsGroup of diseasesSurgical resectionSystemic therapyDistant metastasisSurvival outcomesDiagnosed patientsEpithelial cellsPatientsPatient deathGenetic landscapeCarcinomaDiseaseCancerResectionMetastasis
2023
Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
Tan W, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo C, Nogueras-Gonzalez G, Navai N, Dinney C, Kamat A. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. European Urology Open Science 2023, 53: 16-22. PMID: 37441349, PMCID: PMC10334230, DOI: 10.1016/j.euros.2023.04.013.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerBladder-sparing treatmentLong-term survival outcomesCancer-specific survivalBCG-unresponsive NMIBC patientsEarly radical cystectomyRadical cystectomySurvival outcomesOverall survivalBladder cancerDelayed RCNMIBC patientsEarly RCAnalysis of long-term survival outcomesHigh-grade recurrenceProgression-free rateRecurrence-free rateMedian Follow-UpShort-term outcomesLong-term outcomesCurrent smoker statusCT1 diseaseLymphovascular invasionVariant histologyPrimary endpoint
2021
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, del Monte-Millán M, López-Tarruella S, Consortium I, Adamson K, Albain K, Asare A, Asare S, Balassanian R, Beckwith H, Berry S, Berry D, Boughey J, Buxton M, Chen Y, Chen B, Chien A, Chui S, Clark A, Clennell J, Datnow B, DeMichele A, Duan X, Edmiston K, Elias A, Ellis E, Esserman L, Euhus D, Fadare O, Fan F, Feldman M, Forero-Torres A, Haley B, Han H, Harada S, Haugen P, Helsten T, Hirst G, Hylton N, Isaacs C, Kemmer K, Khan Q, Khazai L, Klein M, Krings G, Lang J, LeBeau L, Leyland-Jones B, Liu M, Lo S, Lu J, Magliocco A, Matthews J, Melisko M, Mhawech-Fauceglia P, Moulder S, Murthy R, Nanda R, Northfelt D, Ocal I, Olopade O, Pambuccian S, Paoloni M, Park J, Parker B, Perlmutter J, Peterson G, Pusztai L, Rendi M, Rugo H, Sahoo S, Sams S, Sanil A, Sattar H, Schwab R, Singhrao R, Steeg K, Stringer-Reasor E, Symmans W, Tawfik O, Tripathy D, Troxell M, Veer L, Venters S, Vinh T, Viscusi R, Wallace A, Wei S, Wilson A, Yau C, Yee D, Zeck J, Boughey J, Goetz M, Hoskin T, Gould R, Valero V, Edge S, Abraham J, Bartlett J, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut S, Thomas J, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin A, Schwensen K, Sharma P, DeMichele A, Cole K, Pusztai L, Kim M, van 't Veer L, Esserman L, Symmans W. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. The Lancet Oncology 2021, 23: 149-160. PMID: 34902335, PMCID: PMC9455620, DOI: 10.1016/s1470-2045(21)00589-1.Peer-Reviewed Original ResearchConceptsResidual cancer burdenEvent-free survivalRCB scoreHER2-positive groupNeoadjuvant chemotherapyBreast cancer subtypesBreast cancerHazard ratioCancer subtypesNodal statusCancer burdenT categoryEvent-free survival eventsPooled patient-level analysisLong-term survival outcomesPractice settingsWorse event-free survivalClinical T categoryHigher RCB scoresStandard pathology reportingHER2-negative patientsHormone receptor statusHER2-negative groupLong-term prognosisPrimary stage I
2019
Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Kim J, Kronbichler A, Eisenhut M, Hong S, van der Vliet H, Kang J, Shin J, Gamerith G. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers 2019, 11: 1798. PMID: 31731749, PMCID: PMC6895916, DOI: 10.3390/cancers11111798.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsProgression-free survivalTumor mutational burdenOverall survivalCheckpoint inhibitorsMutational burdenClinical trials of immune checkpoint inhibitorsPredictive value of tumor mutational burdenEfficacy of immune checkpoint inhibitorsTrials of immune checkpoint inhibitorsResponse to immune checkpoint inhibitorsHazard ratioImmune checkpoint inhibitor benefitTMB groupsImmune checkpoint inhibitor treatmentLow tumor mutational burdenLong-term survival outcomesLow TMB groupsBenefits of OSTMB groupRandomized Controlled TrialsSurvival outcomesRetrospective studyPatient groupClinical trialsO.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response
Brahmer J, Horn L, Hossein B, Ramalingam S, Pluzanski A, Burgio M, Garassino M, Chow L, Gettinger S, Crino L, Planchard D, Butts C, Drilon A, Wojcik-Tomaszewska J, Otterson G, Agrawal S, Li A, Penrod J, Antonia S, Bautista Y. O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response. Journal Of Thoracic Oncology 2019, 14: s1152-s1153. DOI: 10.1016/j.jtho.2019.09.089.Peer-Reviewed Original ResearchOpen Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes
Moschini M, Zamboni S, Soria F, Mathieu R, Xylinas E, Tan W, Kelly J, Simone G, Meraney A, Krishna S, Konety B, Mattei A, Baumeister P, Mordasini L, Montorsi F, Briganti A, Gallina A, Stabile A, Sanchez-Salas R, Cathelineau X, Rink M, Necchi A, Karakiewicz P, Rouprêt M, Koupparis A, Kassouf W, Scherr D, Ploussard G, Boorjian S, Lotan Y, Sooriakumaran P, Shariat S. Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. Journal Of Clinical Medicine 2019, 8: 1192. PMID: 31395826, PMCID: PMC6722857, DOI: 10.3390/jcm8081192.Peer-Reviewed Original ResearchRobot-assisted radical cystectomyOpen radical cystectomyCancer-specific mortalitySurvival outcomesRadical cystectomyPropensity score matchingBladder cancerPatients treated with robot-assisted radical cystectomyAssociation of surgical techniqueLong-term survival outcomesCancer-specific mortality ratesMultivariate Cox regression analysisMultivariate competing risk analysisOpen radical cystectomy patientsRobot-assisted radical cystectomy patientsBilateral pelvic lymphadenectomyCompare survival outcomesMedian Follow-UpUrothelial bladder cancerScore matchingCox regression analysisPropensity-matched cohortCompeting Risk AnalysisPelvic lymphadenectomyMulticentre cohort
2016
Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis
Njei B, McCarty TR, Birk JW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis. Journal Of Gastroenterology And Hepatology 2016, 31: 1141-1146. PMID: 26749521, PMCID: PMC4885788, DOI: 10.1111/jgh.13289.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAge FactorsAgedCarcinoma, Squamous CellEarly Detection of CancerEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsRetrospective StudiesRisk FactorsSEER ProgramSurvival RateTime FactorsTreatment OutcomeUnited StatesConceptsSquamous cell carcinomaEsophageal cancerEsophageal adenocarcinomaMedian survivalBetter long-term survival outcomesLong-term survival outcomesOverall median survivalEnd Results (SEER) databaseProportion of patientsSEER database analysisSignificant survival improvementProportional hazards regressionEsophageal cancer survivalLong-term survivalIndependent mortality factorsLocalized diseaseCurative stageSurgical treatmentSurvival improvementHazards regressionResults databaseSurvival outcomesCell carcinomaTreatment modalitiesCancer survival
2012
O-4 Intestinal Transplantation for End Stage Crohn's Disease: Therapeutic Efficacy and Disease Recurrence
Koritsky D, Costa G, Bond G, Schuster B, Roberts M, Hoffman B, Stein W, Soltys K, Sogawa H, Rubin E, Regueiro M, Abu-Elmagd K. O-4 Intestinal Transplantation for End Stage Crohn's Disease: Therapeutic Efficacy and Disease Recurrence. Inflammatory Bowel Diseases 2012, 18: s3-s3. DOI: 10.1097/00054725-201212001-00005.Peer-Reviewed Original ResearchIrreversible intestinal failureDisease recurrenceCrohn's diseaseRecipient pretreatmentSurvival rateChronic rejectionGraft lossIntestinal failureMultivisceral transplantationTPN therapySurvival outcomesGraft functionIntestinal transplantationTherapeutic efficacyActuarial patient survival ratesLong-term survival outcomesRisk of graft lossPositive lymphocytotoxic crossmatchDisease patientsConsecutive adult patientsYear survival rateTime of transplantationNon-Crohn's disease patientsPatient survival ratesLong-term outcomes
2008
Is There a Difference in Survival Between Right- Versus Left-Sided Colon Cancers?
Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is There a Difference in Survival Between Right- Versus Left-Sided Colon Cancers? Annals Of Surgical Oncology 2008, 15: 2388. PMID: 18622647, PMCID: PMC3072702, DOI: 10.1245/s10434-008-0015-y.Peer-Reviewed Original ResearchConceptsRight-sided colon cancerLeft-sided colon cancerProportional hazards regression analysisHazards regression analysisColon cancerMedian survivalCox proportional hazards regression analysisLongitudinal population-based databaseLong-term survival outcomesEnd Results Program databaseInvasive colon adenocarcinomaRight-sided cancersOverall median survivalLeft-sided cancersYear of diagnosisPopulation-based databaseRetrospective survival analysisSubset of subjectsRegression analysisSEER databaseSurgical resectionLymph nodesWorse prognosisSurvival outcomesTumor size
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply